Oramed invests $36.9M in Alpha Tau, acquires 14.1M shares at $2.612/share

ORAMED PHARMACEUTICALS INC.

Oramed subsidiary purchased ~14.1M shares of Alpha Tau (NASDAQ: DRTS) for $36.9M ($2.612/share) via registered direct offering.
Oramed gets right to nominate two directors to Alpha Tau board; board size capped at 8 without Oramed's consent.
Concurrent 3-year IR/PR services agreement; Oramed receives $3M fee plus warrants to buy ~3.24M shares at $3.474-$3.90.
Partnership aims to support Alpha Tau's alpha-radiation cancer therapy Alpha DaRT, including US trials and manufacturing scale-up.
Oramed CEO Nadav Kidron cites alignment in transforming therapeutic delivery; governance role allows strategic influence.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.